胃肠间质瘤术后肝转移的治疗——附8例报告  

The treatment of postoperative hepatic metastases of gastrointestinal stromal tumors

作　　者：丁德权[1] 曹齐生[1] 王珏[1] 

机构地区：[1]安徽省马鞍山市人民医院,安徽马鞍山243000

出　　处：《罕少疾病杂志》2009年第5期13-15,共3页Journal of Rare and Uncommon Diseases

摘　　要：目的探索胃肠间质瘤术后肝转移的治疗方法。方法4例胃肠间质瘤术后肝转移患者采用TACE(肝动脉化疗栓塞术)3～8次,栓塞剂为超液化碘油加PVA(聚乙烯醇)颗粒加平阳霉素,4例给予口服格列卫(甲磺酸伊马替尼)400mg/日,随访3年,比较两组病例平均生存期和疾病无进展时间(TTP)。结果TACE治疗组中1例患者经过4次TACE获得二次手术机会,生存期已超过3年;另3例患者1年生存率为50%,TTP为9个月,平均生存期为10.7个月;口服甲磺酸伊马替尼治疗组1年生存率为75%,TTP为11.5个月,平均生存期为14个月。结论甲磺酸伊马替尼治疗效果优于肝动脉化疗栓塞术。Objective To explore the treatment methods for postoperative hepatic metastases of gastrointestinal stromal tumors. Methods Four cases of patients with postoperative hepatic metastases of gastrointestinal stromal tumors were treated with TACE （transcatheter arterial chemoembolization） for 3 to 8 times~ the embolic agent was composed of ultra-fluid lipiodol ＋ PVA （polyvinyl alcohol） ＋ pingyangmycim these four patients were given 400mg of imatinib mesylate a day by mouth and followed up for 3 years~ the values of MST （mean survival time） and TTP （time to progression of disease-free） of two groups were compared in this paper. Results In TACE treatment group, one patient got a second operation chance after 4 times of TACE treatment and the life span of that patient had exceeded 3 years~ one year survival rate of the other 3 patients was 50% and their TTP was 9 months, and the average life span of them was 10.7 months, in imatinib mesylate treatment group, one year survival rate of the patients was 75% and their TTP was 11.5 months, and the average life span of them was 14 months. Conclusion The curative effect of imatinib mesylate is better than that of TACE.

关 键 词：胃肠间质瘤术后肝转移 肝动脉化疗栓塞术 甲磺酸伊马替尼 

分 类 号：R735[医药卫生—肿瘤]